Resource Summary Report

Generated by dkNET on May 6, 2025

GARNET

RRID:SCR_012033
Type: Tool

Proper Citation

GARNET (RRID:SCR_012033)

Resource Information

URL: http://biome.ewha.ac.kr:8080/GSEAWebApp/

Proper Citation: GARNET (RRID:SCR_012033)

Description: An integrative platform for diverse types of gene set analysis with annotation network navigation. It includes tools for statistical analysis, visualization of annotation relationships, retrieval of genes from annotation database, and set operation for gene sets. In an effort to allow access to a full spectrum of amassed biological knowledge, they have integrated a variety of annotation data that include the GO, domain, disease, drug, chromosomal location, and custom-defined annotations. Diverse types of molecular networks (pathways, transcription and microRNA regulations, protein-protein interaction) are also included. The pair-wise relationship between annotation gene sets was calculated using kappa statistics. GARNET consists of three modules--gene set manager, gene set analysis and gene set retrieval, which are tightly integrated to provide virtually automatic analysis for gene sets. A dedicated viewer for annotation network has been developed to facilitate exploration of the related annotations.

Abbreviations: GARNET

Synonyms: Gene Annotation Relationship NEtwork Tools

Resource Type: analysis service resource, production service resource, service resource, data analysis service

Defining Citation: PMID:21342555

Keywords: statistical analysis, visualization, annotation, gene

Funding:

Resource Name: GARNET

Resource ID: SCR_012033

Alternate IDs: OMICS_02224

Alternate URLs: http://ercsb.ewha.ac.kr/garnet/

Old URLs: http://ercsb.ewha.ac.kr:8080/GSEAWebApp/index.jsp, http://garnet.isysbio.org/

Record Creation Time: 20220129T080308+0000

Record Last Update: 20250506T061141+0000

Ratings and Alerts

No rating or validation information has been found for GARNET.

No alerts have been found for GARNET.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET.

Shulgina Y, et al. (2024) RNA language models predict mutations that improve RNA function. Nature communications, 15(1), 10627.

Shulgina Y, et al. (2024) RNA language models predict mutations that improve RNA function. bioRxiv : the preprint server for biology.

Oaknin A, et al. (2023) Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(22), 4564.

Austin D, et al. (2023) Comparative analysis of PD-1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL-2 stimulation data. CPT: pharmacometrics & systems pharmacology, 12(1), 87.

Goulden S, et al. (2023) Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the

National Cancer Registration Service in England. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 33(11), 1715.

André T, et al. (2023) Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial. JAMA network open, 6(11), e2341165.

Goulden S, et al. (2023) Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm. Journal of health economics and outcomes research, 10(2), 53.

Borges AL, et al. (2022) Widespread stop-codon recoding in bacteriophages may regulate translation of lytic genes. Nature microbiology, 7(6), 918.

Unsal-Beyge S, et al. (2022) Functional stratification of cancer drugs through integrated network similarity. NPJ systems biology and applications, 8(1), 11.

Mathews C, et al. (2022) An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer. The oncologist, 27(12), 1058.

Melhem M, et al. (2022) Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours. British journal of clinical pharmacology, 88(9), 4142.

Patnaik A, et al. (2022) Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. Cancer chemotherapy and pharmacology, 89(1), 93.

Oaknin A, et al. (2022) Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. Journal for immunotherapy of cancer, 10(1).

Wu D, et al. (2021) Graves' Disease and Rheumatoid Arthritis: A Bidirectional Mendelian Randomization Study. Frontiers in endocrinology, 12, 702482.

Moslehi R, et al. (2020) Integrative genomic analysis implicates ERCC6 and its interaction with ERCC8 in susceptibility to breast cancer. Scientific reports, 10(1), 21276.

Ferenci P, et al. (2019) Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. Journal of viral hepatitis, 26(6), 685.

Wilson JL, et al. (2016) Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia. Integrative biology : quantitative biosciences from nano to macro, 8(7), 761.

Hale PJ, et al. (2012) Genome-wide meta-analysis of genetic susceptible genes for Type 2 Diabetes. BMC systems biology, 6 Suppl 3(Suppl 3), S16.